RT Journal Article SR Electronic T1 Global DNA hypomethylation in epithelial ovarian cancer: passive demethylation and association with genomic instability JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.01.22.20018374 DO 10.1101/2020.01.22.20018374 A1 Wa Zhang A1 David Klinkebiel A1 Carter J Barger A1 Sanjit Pandey A1 Chittibabu Guda A1 Austin Miller A1 Stacey N. Akers A1 Kunle Odunsi A1 Adam R. Karpf YR 2020 UL http://medrxiv.org/content/early/2020/02/10/2020.01.22.20018374.abstract AB A hallmark of human cancer is global DNA hypomethylation (GDHO), but the mechanisms accounting for this defect and its pathological consequences have not been defined in human epithelial ovarian cancer (EOC). In EOC, GDHO was associated with advanced disease and reduced overall and disease-free survival. GDHO(+) EOC was enriched for a proliferative gene expression signature, including CCNE1 and FOXM1 overexpression. DNA hypomethylation preferentially occurred within genomic blocks (hypomethylated blocks) overlapping late-replicating, lamina-associated domains, PRC2 binding, and H3K27me3. Increased proliferation coupled with hypomethylated block formation at late replicating regions suggested passive hypomethylation, which was further supported by the observation that cytosine DNA methyltransferases (DNMTs) and UHRF1 showed significantly reduced expression in GDHO(+) EOC, after normalization to proliferation markers. Importantly, GDHO(+) EOC showed elevated chromosomal instability (CIN), and copy number alterations (CNA) were enriched at hypomethylated blocks. Together, these findings implicate a passive demethylation mechanism for GDHO that promotes genomic instability and poor prognosis in EOC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAll funding is reported in the contents of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is provided in the contents of the manuscript.CG genecancer germline or cancer testis geneCINchromosomal instabilityCNAcopy number alterationDACdecitabine, 5-aza-2’-deoxycytidineDEGdifferentially expressed geneDE-CG genedifferentially expressed CG geneDMCdifferentially methylated CpG siteDMRdifferentially methylated regionDNMTcytosine DNA methyltransferaseEOCepithelial ovarian cancerFDRfalse discovery rateFTEfallopian tube epitheliaGDHOglobal DNA hypomethylationGSEAgene set enrichment analysisHGSOChigh grade serous ovarian cancerIPAIngenuity Pathway AnalysisLADlamina-associated domainNEnormal epithelia (OSE + FTE)NObulk normal ovaryOSEovarian surface epitheliaPCAprincipal component analysisRErepetitive DNA elementsRMArobust multichip averageTETTen-eleven translocation methylcytosine dioxygenaseTFtranscription factor